Want to see HK:1177 full AI Analyst Report?
Top Page
Sino Biopharmaceutical
(1177)
Select Model
Select Model
Rating:55Neutral
Price Target:
HK$5.00
▼(-16.67% Downside)
Action:Reiterated
Date:05/03/26
The score is primarily supported by solid financial performance, especially strong gross profitability and improved free cash flow. It is meaningfully weighed down by weak technicals (price below key moving averages with negative MACD) and a demanding valuation (high P/E with only a modest dividend yield).
Positive Factors
High Gross Margins
Sino Biopharm's sustained gross margins near 78%–83% indicate durable product-level profitability and pricing power in its branded portfolio. High gross margins support funding for R&D and commercialization and provide a structural buffer to absorb SG&A or pricing pressures over months.
Negative Factors
Net Margin Decline & Volatility
A sharp drop in net margin reduces confidence in sustainable profitability and makes earnings less predictable. Volatile bottom-line performance complicates capital allocation and may constrain the company’s ability to consistently fund growth initiatives or absorb cost shocks over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
Sino Biopharm's sustained gross margins near 78%–83% indicate durable product-level profitability and pricing power in its branded portfolio. High gross margins support funding for R&D and commercialization and provide a structural buffer to absorb SG&A or pricing pressures over months.
Read all positive factors
Sino Biopharmaceutical (1177) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$88.68B
Dividend Yield1.4%
Average Volume (3M)114.93M
Price to Earnings (P/E)33.1
Beta (1Y)0.94
Revenue Growth10.20%
EPS Growth30.38%
CountryHK
Employees21,435
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.13
Shares Outstanding18,682,953,000
10 Day Avg. Volume98,005,928
30 Day Avg. Volume114,926,811
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)3.27
Price to Sales (P/S)3.15
P/FCF Ratio13.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$8.45Price Target Upside40.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.23
Revenue Forecast (FY)HK$36.22B
Sino Biopharmaceutical Business Overview & Revenue Model
Company Description
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medi...
How the Company Makes Money
Sino Biopharmaceutical primarily makes money by selling proprietary and in-licensed prescription drugs in China. Revenue is mainly generated from (1) product sales of branded pharmaceuticals to hospitals and other healthcare providers (a key chann...
Sino Biopharmaceutical Financial Statement Overview
Summary
Income Statement
67
Positive
Balance Sheet
64
Positive
Cash Flow
74
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 31.83B | 28.87B | 26.20B | 26.03B | 26.86B |
| Gross Profit | 26.13B | 23.53B | 21.21B | 21.54B | 21.53B |
| EBITDA | 7.26B | 6.11B | 6.98B | 6.69B | 19.87B |
| Net Income | 2.34B | 3.50B | 2.33B | 2.54B | 14.61B |
Balance Sheet | |||||
| Total Assets | 76.04B | 65.41B | 63.60B | 64.06B | 60.54B |
| Cash, Cash Equivalents and Short-Term Investments | 22.96B | 14.60B | 14.12B | 16.92B | 15.79B |
| Total Debt | 16.08B | 9.78B | 12.58B | 13.98B | 12.12B |
| Total Liabilities | 33.32B | 22.63B | 25.43B | 26.12B | 22.81B |
| Stockholders Equity | 30.68B | 31.96B | 30.47B | 29.75B | 30.29B |
Cash Flow | |||||
| Free Cash Flow | 7.59B | 5.22B | 4.36B | 4.56B | 3.47B |
| Operating Cash Flow | 9.29B | 6.62B | 6.07B | 6.27B | 5.37B |
| Investing Cash Flow | -12.41B | -1.71B | -756.98M | -4.07B | -2.52B |
| Financing Cash Flow | 4.16B | -6.32B | -6.55B | -3.19B | -3.23B |
Sino Biopharmaceutical Technical Analysis
Negative
6.00
Price Trends
4.89
Positive
5.40
Negative
6.17
Negative
Market Momentum
0.11
Negative
53.16
Neutral
59.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1177, the sentiment is Negative. The current price of 6 is above the 20-day moving average (MA) of 4.76, above the 50-day MA of 4.89, and below the 200-day MA of 6.17, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 53.16 is Neutral, neither overbought nor oversold. The STOCH value of 59.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1177.
Sino Biopharmaceutical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$154.85B | 154.62 | 4.82% | ― | 38.55% | ― | |
69 Neutral | HK$40.99B | 4.10 | 38.96% | 0.95% | 95.27% | 304.20% | |
61 Neutral | HK$31.49B | 32.88 | 23.99% | ― | 16.65% | 0.87% | |
55 Neutral | HK$88.68B | 33.10 | 7.24% | 1.40% | 10.20% | 30.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$81.38B | -62.68 | -14.26% | ― | 44.03% | -108.83% | |
43 Neutral | HK$35.64B | -54.00 | -10.78% | ― | 34.19% | 47.97% |
* Healthcare Sector Average
HK:1177
Sino Biopharmaceutical
4.98
-1.78
-26.31%
HK:1801
Innovent Biologics
88.95
0.30
0.34%
HK:1530
3SBio
16.15
-13.65
-45.81%
HK:9926
Akeso, Inc.
88.35
-52.15
-37.12%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
17.64
-7.46
-29.72%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
57.75
-6.85
-10.60%
Sino Biopharmaceutical Corporate Events
Sino Biopharm Deepens GSK Respiratory Deal to Cement China Lead
Jul 8, 2026
Sino Biopharmaceutical is a leading Chinese pharmaceutical group with a strong presence in respiratory, oncology and liver disease therapies. Through subsidiary Chia Tai Tianqing Pharmaceutical, it has built one of China’s largest innovative...
Sino Biopharm Strikes $2.1 Billion Global Respiratory Drug Deal with AstraZeneca
Jul 7, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has signed an exclusive license agreement with AstraZeneca granting the British drugmaker rights to develop, manufacture and commercialize the inhaled PDE3/4 inhibitor TQC3721 outside Chi...
Sino Biopharm’s Long-Acting Ropivacaine Analgesic Wins NDA Acceptance in China
Jul 3, 2026
Sino Biopharmaceutical’s subsidiary Beijing Tide Pharmaceutical has had its new drug application for a ropivacaine hydrochloride sustained-release solution accepted by China’s Center for Drug Evaluation, targeting postoperative long-ac...
Sino Biopharmaceutical Wins Priority Review for CLDN18.2 Gastric Cancer Drug
Jun 23, 2026
Sino Biopharmaceutical’s subsidiary LaNova Medicines has had its new drug application for tecotabart vedotin, a CLDN18.2-targeting antibody-drug conjugate known as LM-302, accepted by China’s Center for Drug Evaluation for CLDN18.2-pos...
Sino Biopharmaceutical Wins China Approval for First-in-Class Peceleganan Spray
Jun 23, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has secured approval from China’s National Medical Products Administration for Peceleganan Spray, a national Category 1 innovative drug for treating wound infections from first-degr...
Sino Biopharmaceutical Adds Leading Scientists to Board as Independent Directors
Jun 17, 2026
Sino Biopharmaceutical has appointed renowned scientists Dr. Chen Lieping and Dr. Lu Bai as independent non-executive directors, effective after its annual general meeting on 17 June 2026. The move brings high-profile expertise in cancer immunothe...
Sino Biopharmaceutical Details Board Composition and Governance Committee Roles
Jun 17, 2026
Sino Biopharmaceutical has confirmed the current composition of its board, listing five executive directors, including chairwoman Theresa Tse and CEO Eric Tse, alongside six independent non‑executive directors. The disclosure reinforces the ...
Sino Biopharmaceutical Wins Strong Shareholder Backing at 2026 AGM
Jun 17, 2026
Sino Biopharmaceutical shareholders approved all resolutions at the 17 June 2026 annual general meeting, including adoption of the 2025 audited financial statements and the payment of a final dividend. Investors also backed the re-election of dire...
Sino Biopharm’s ST2 Antibody Shows Promising Phase II Results in Allergic Rhinitis
Jun 15, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing reported Phase II data for TQC2938, a humanised ST2 monoclonal antibody, in adults with moderate-to-severe seasonal allergic rhinitis who had inadequate response to standard intranasal co...
Sino Biopharmaceutical Unveils HK$2 Billion Share Purchase Plan to Support Stock and Shareholders
Jun 14, 2026
Sino Biopharmaceutical’s board has launched a share purchase plan in response to recent share price volatility, arguing that the company’s value is being significantly underestimated by the market. The plan allows for up to HK$2 billio...
Sino Biopharm’s Culmerciclib Shows Promise in Resistant Breast Cancer
Jun 1, 2026
Sino Biopharmaceutical reported Phase II data for its oral CDK2/4/6 inhibitor culmerciclib, combined with fulvestrant, in hormone receptor-positive, HER2-negative advanced breast cancer patients who had progressed on prior CDK4/6 inhibitor and end...
Sino Biopharm’s LM-302 Gastric Cancer Data Pave Way for Chemo‑Free Phase III Trial
May 31, 2026
Sino Biopharmaceutical announced Phase II clinical results for tecotabart vedotin (LM-302), a CLDN18.2-targeting antibody-drug conjugate developed by subsidiary LaNova Medicines, in first-line treatment of CLDN18.2-positive advanced gastric or gas...
Sino Biopharm Showcases Promising Phase I Data for Novel EGFR/c-Met ADC at ASCO 2026
May 31, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has reported Phase I data for TQB6411, an EGFR/c-Met antibody-drug conjugate, in patients with advanced solid tumors who had failed standard therapies. The drug, one of the first EGFR/c-M...
Sino Biopharm Reports Landmark Phase III Win for Benmelstobart Combo in Lung Cancer
May 31, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has reported Phase III data showing that its anti-PD-L1 antibody benmelstobart combined with platinum chemotherapy, followed by benmelstobart plus anlotinib, significantly extended progre...
Sino Biopharm Wins China-Wide Approval for Opioid-Induced Constipation Drug
May 29, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has secured National Medical Products Administration approval to market Naldemedine Tosylate Tablets in China for opioid-induced constipation in adults, extending earlier regional clearan...
Sino Biopharm, GSK Report Pivotal Phase III Success for Hepatitis B Drug Bepirovirsen
May 28, 2026
Sino Biopharmaceutical said its subsidiary Chia Tai Tianqing and partner GSK have reported positive pivotal data from two Phase III trials of bepirovirsen for chronic hepatitis B. The results, unveiled at the EASL 2026 Congress and published in th...
Sino Biopharm’s IDH1 Inhibitor for Biliary Tract Cancer Wins Priority Review in China
May 28, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has advanced its innovative IDH1 inhibitor TQB3454, designed to treat patients with locally advanced, recurrent, or metastatic biliary tract cancer harboring IDH1 mutations who have faile...
Sino Biopharm’s Liver-Targeted THR Agonist Kylo-0603 Shows Favorable Phase I Data
May 27, 2026
Sino Biopharmaceutical announced Phase I clinical data for Kylo-0603, an orally administered GalNAc-conjugated thyroid hormone receptor-beta small molecule agonist developed by its subsidiary Hygieia, presented at the 2026 European Association for...
Sino Biopharm’s Bispecific Antibody M701 Shows Promise in Malignant Effusion Trials
May 22, 2026
Sino Biopharmaceutical said subsidiary Chia Tai Tianqing will present data at the 2026 ASCO meeting from two clinical studies of M701, a CD3/EpCAM bispecific antibody targeting malignant effusions caused by advanced epithelial tumors and non-small...
Sino Biopharmaceutical Wins China First-Line Approval for Oral HER2 Lung Cancer Drug
May 21, 2026
Sino Biopharmaceutical announced that zongertinib, an oral HER2 tyrosine kinase inhibitor it co-promotes with Boehringer Ingelheim, has received conditional approval from China’s National Medical Products Administration as a first-line monot...
Sino Biopharm Showcases Promising Obesity Antibody Data and Expands Weight-Loss Pipeline
May 13, 2026
Sino Biopharmaceutical announced that subsidiary Chia Tai Tianqing has presented preclinical data for TQF6422, a fully human ActRII A/B monoclonal antibody, at the European Congress on Obesity 2026. The drug is designed to promote skeletal muscle ...
Sino Biopharm, GSK in exclusive China pact for breakthrough hepatitis B drug
May 11, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has entered an exclusive strategic collaboration with GSK to commercialise bepirovirsen for chronic hepatitis B in mainland China. CTTQ will handle importation, distribution and market ac...
Sino Biopharm Wins NMPA Review Nod for First Domestic CD3/EpCAM Bispecific Antibody
May 7, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has had its new drug application for M701, China’s first independently developed CD3/EpCAM bispecific antibody, accepted by the Center for Drug Evaluation of the National Medical Pr...
Sino Biopharm Advances First-in-Class CCR8 Antibody Into Phase III Gastric Cancer Trial
May 6, 2026
Sino Biopharmaceutical announced that its subsidiary LaNova Medicines has enrolled the first patient in a Phase III registrational clinical trial of cafelkibart (LM-108), a CCR8 monoclonal antibody, as a second-line treatment for CCR8-positive loc...
Sino Biopharmaceutical Wins China Nod for First-Line Use of Novel Breast Cancer Drug
May 6, 2026
Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing has secured Chinese regulators’ approval for a new first-line indication of its national Category 1 innovative drug culmerciclib, a global first-in-class CDK2/4/6 inhibitor, in comb...
Sino Biopharmaceutical Plans Board Changes Ahead of 2026 AGM
Apr 29, 2026
Sino Biopharmaceutical has announced planned board changes at its 2026 annual general meeting, with executive director Tian Zhoushan stepping down from the board due to an internal reallocation of responsibilities while retaining his management ro...
Sino Biopharm Sets Hybrid AGM, Seeks Fresh Share Issue Mandate
Apr 29, 2026
Sino Biopharmaceutical has called its next annual general meeting for 17 June 2025 in hybrid format, combining an in-person session in Hong Kong with an online e-voting platform to facilitate broader shareholder participation. The agenda includes ...
Sino Biopharmaceutical Bolsters Leadership for Global Clinical Development
Apr 28, 2026
Sino Biopharmaceutical has strengthened its senior medical leadership by appointing Dr. Kang Xiaoyan as Chief Medical Officer, with responsibility for global clinical development and collaborations for innovative drugs across all therapeutic areas...
Sino Biopharm Unit LaNova Unveils Promising ADC Data at AACR 2026
Apr 21, 2026
Sino Biopharmaceutical’s wholly owned unit LaNova Medicines has showcased new preclinical data on two antibody-drug conjugates, LM-364 and LM-338, at the American Association for Cancer Research Annual Meeting 2026, underscoring its push int...
Sino Biopharm Wins China Approval for New Alveolar Soft Part Sarcoma Therapy
Apr 20, 2026
Sino Biopharmaceutical announced that its subsidiary’s drugs Benmelstobart, an anti-PD-L1 monoclonal antibody, and Anlotinib, a multi-targeted tyrosine kinase inhibitor, have been approved in China as a combination therapy for advanced or un...
Sino Biopharm Reports Promising Early Data for PD-1/VEGF Bispecific Cancer Drug Licensed to Merck
Apr 19, 2026
Sino Biopharmaceutical announced that its subsidiary LaNova Medicines presented preliminary clinical data at a major cancer research conference for MK-2010/LM-299, an investigational PD-1/VEGF tetravalent bispecific antibody for advanced solid tum...
Sino Biopharm Advances CLDN18.2 ADC With First Patient Dosed in Global Phase III Gastric Cancer Trial
Apr 15, 2026
Sino Biopharmaceutical said its subsidiary LaNova Medicines has enrolled the first patient in a Phase III registrational trial of tecotabart vedotin, an antibody-drug conjugate targeting CLDN18.2, as a first-line, chemotherapy-free combination wit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.